GlassScriptPhysician profile
Khaja Asadullah
NPI 1578515409
$1,731.90
in general payments reported to CMS, 2019-2025
33 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Geriatric Medicine (Internal Medicine) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $71.62 · 2021: $383 · 2022: $361 · 2023: $223 · 2024: $144 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $195.57 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Janssen Pharmaceuticals, INC | $159.95 | 2020-2022 | |
| Electromed, INC. | $145.25 | 2021-2022 | |
| Amgen INC. | $98.90 | 2019-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $80.22 | 2019-2022 | |
| Pfizer INC. | $78.24 | 2019-2023 | |
| Abbott Laboratories | $76.96 | 2022-2025 | Proclaim, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.37 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $71.11 | 2021 | |
| Corcept Therapeutics | $66.12 | 2024-2025 | Korlym |
| Merz North America, INC. | $62.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $54.05 | 2019-2023 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $52.02 | 2019 | |
| Lilly USA, LLC | $48.09 | 2025 | Mounjaro |
| Shire North American Group INC | $46.65 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $39.36 | 2023 | |
| Astellas Pharma US INC | $38.42 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $34.55 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $31.97 | 2021-2024 | Lokelma |
| Recordati_rare_diseases_inc. | $30.96 | 2025 | Isturisa |
| Sun Pharmaceutical Industries INC. | $24.59 | 2021 | |
| Allergan, INC. | $23.86 | 2020 | |
| Dexcom, INC. | $23.57 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $23.07 | 2024 | |
| Amphastar Pharmaceuticals, INC. | $21.93 | 2024 | |
| Koya Medical, INC. | $21.29 | 2024 | Dayspring, Koya Medical |
| Ultragenyx Pharmaceutical INC. | $18.13 | 2021 | |
| Acella Pharmaceuticals, LLC | $16.81 | 2025 | NP Thyroid 60 |
| Urovant Sciences INC | $16.62 | 2021 | |
| Exact Sciences Corporation | $15.10 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $14.90 | 2023 | Nuedexta |
| Esperion Therapeutics, INC. | $14.63 | 2025 | Nexletol |
| Antares Pharma, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khaja Asadullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.